

27th April, 2024

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘SEBI Listing Regulations’)

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform that the Company has received on 26th April 2024 assessment orders from the Office of The Navi Mumbai Municipal Corporation, Cess Department (‘Orders’), levying penalty aggregating to Rs. 3,500/- under the Bombay Provincial Municipal Corporation (Cess on Entry of Goods) Rules, 1996.

The Orders were passed in connection with the disclosure requirement of cess liability in returns for the pre-acquisition period 1st April, 2008 to 31st March, 2011 and 1st April, 2012 to 31st March, 2013 in the matter of Hemmo Pharmaceuticals Private Limited, which amalgamated with the Company in August, 2022.

The said Orders does not have any material impact on financials, operation or other activities of the Company.

Kindly take the above on record and oblige.

Yours truly,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

piramalpharma.com